Hengrui SHR6390 intends to be included in the breakthrough therapy CDK4/6 inhibitor mixture...
Flt3 inhibitor AML produces CR: talk about off-target...
Kelun RET inhibitor reaches overseas authorization
CStone's KIT/PDGFRA mutant kinase inhibitor avatinib was approved in China
List of synthetic routes of the second generation ALK inhibitor Alectinib
PI3K dual inhibitor!
Nuocheng Jianhua's RTK inhibitor ICP-033 new drug research application was approved by the National Drug Administration...
"First-in-class" JAK inhibitors obtained FDA priority review qualification
New ADC drug Padcev filed in Japan for the treatment of patients refractory to PD-(L)1 inhibitors
Deqi Pharmaceuticals will release preclinical data of dual-target inhibitor combination therapy
Ascent Pharma's third-generation BCR-ABL inhibitor plans to be included in breakthrough treatment products
Market | Rising stars are rising, the CDK4/6 inhibitor market is getting bigger and bigger
Pfizer's BRAF inhibitor is approved for clinical treatment of colorectal cancer in China
New oral TYK2 inhibitor!
CStone's platinib enters China for approval and is expected to usher in the first approved RET inhibitor
Roche withdraws PD-L1 inhibitor Tecentriq for bladder cancer indications in the U.S.
CDE intends to identify Hengrui CDK4/6 inhibitors and Junshi anti-PD-1 for breakthrough therapy
The PI3Kδ inhibitors introduced by Cinda Biosystems are planned to be included in breakthrough treatment products
What changes will the introduction of IL-17A inhibitors into medical insurance bring to the AS "ecological circle"?
of new protein inhibitors has important reference significance for the control of tumor blood-borne metastasis